产品名称

产品货号

Axon 2327 CAS [1361198-79-9] MF C17H20N6O4MW 372.38 Purity: 99% Optical purity: Optically pure Soluble in DMSO Description Novel DNA alkylating agent exhibiting superior activity against breast cancer cells in vitro and intracranial triple-negative tumor growth in vivo (IC50 values 5-50 µM for cytotoxicity on glioma cell lines). NEO 212 causes DNA damage and cell death much more efficiently than TMZ, because linkage with POH increased its biological half-life and thus provided greater opportunity for placement of cytotoxic DNA lesions.NEO212 is a conjugate of temozolomide (TMZ, Axon 2326) with the natural product perillyl alcohol (POH) and circumvents TMZ-resistance in multiple cancer cell lines and gliomas. References Certificates Categories Extra info T.C. Chen et al. A novel temozolomide-perillyl alcohol conjugate exhibits superior activity against breast cancer cells in vitro and intracranial triple-negative tumor growth in vivo. Mol. Cancer Ther. 2014, 13, 1181-1193. H.Y. Cho et al. NEO212, temozolomide conjugated to perillyl alcohol, is a novel drug for effective treatment of a broad range of temozolomide-resistant gliomas. Mol. Cancer Ther. 2014, 13, 2004-2017. Certificate of Analysis Material Safety Data Sheet Apoptosis Cell Cycle Regulation Cell Signaling & Oncology DNA-damage Response DNA DNA alkylating agent; chemotherapeutic Chemical name (S)-(4-(Prop-1-en-2-yl)cyclohex-1-enyl)methyl 3-methyl-4-oxo-3,4-dihydroimidazo[5,1-d][1,2,3,5]tetrazine-8-carbonylcarbamate Parent CAS No. [1361198-79-9] Order Size Unit Price Stock 5 mg €110.00 In Stock

产品价格

现货询价，电话：010-67529703

产品规格

产品品牌

axonmedchem

产品概述

产品详情

NEO 212 - TMZ-POH

Based on 8 reference(s) in Google Scholar 9 10 8

Axon 2327

CAS [1361198-79-9]

MF C17H20N6O4
MW 372.38

Purity: 99%
Optical purity: Optically pure
Soluble in DMSO

NEO 212

Description

Novel DNA alkylating agent exhibiting superior activity against breast cancer cells in vitro and intracranial triple-negative tumor growth in vivo (IC50 values 5-50 µM for cytotoxicity on glioma cell lines). NEO 212 causes DNA damage and cell death much more efficiently than TMZ, because linkage with POH increased its biological half-life and thus provided greater opportunity for placement of cytotoxic DNA lesions.
NEO212 is a conjugate of temozolomide (TMZ, Axon 2326) with the natural product perillyl alcohol (POH) and circumvents TMZ-resistance in multiple cancer cell lines and gliomas.

T.C. Chen et al. A novel temozolomide-perillyl alcohol conjugate exhibits superior activity against breast cancer cells in vitro and intracranial triple-negative tumor growth in vivo. Mol. Cancer Ther. 2014, 13, 1181-1193.

H.Y. Cho et al. NEO212, temozolomide conjugated to perillyl alcohol, is a novel drug for effective treatment of a broad range of temozolomide-resistant gliomas. Mol. Cancer Ther. 2014, 13, 2004-2017.

DNA alkylating agent; chemotherapeutic

Chemical name

(S)-(4-(Prop-1-en-2-yl)cyclohex-1-enyl)methyl 3-methyl-4-oxo-3,4-dihydroimidazo[5,1-d][1,2,3,5]tetrazine-8-carbonylcarbamate

Parent CAS No.

[1361198-79-9]

产品资料